13.11
price down icon4.45%   -0.61
pre-market  Vorhandelsmarkt:  13.11  
loading
Schlusskurs vom Vortag:
$13.72
Offen:
$13.75
24-Stunden-Volumen:
2.02M
Relative Volume:
0.82
Marktkapitalisierung:
$325.06M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-3.5722
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
-11.84%
1M Leistung:
+212.89%
6M Leistung:
+18.75%
1J Leistung:
-23.69%
1-Tages-Spanne:
Value
$12.87
$13.75
1-Wochen-Bereich:
Value
$12.87
$15.61
52-Wochen-Spanne:
Value
$3.42
$18.15

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Firmenname
Urogen Pharma Ltd
Name
Telefon
972 9 770 7601
Name
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Name
Mitarbeiter
234
Name
Twitter
@UroGenPharma
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
URGN's Discussions on Twitter

Vergleichen Sie URGN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
URGN
Urogen Pharma Ltd
13.11 325.06M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-16 Hochstufung H.C. Wainwright Neutral → Buy
2025-05-22 Herabstufung H.C. Wainwright Buy → Neutral
2025-04-16 Eingeleitet Scotiabank Sector Outperform
2025-02-19 Fortgesetzt Ladenburg Thalmann Buy
2024-08-22 Eingeleitet Guggenheim Buy
2023-02-08 Herabstufung Jefferies Buy → Hold
2022-04-27 Eingeleitet Berenberg Buy
2020-04-16 Bestätigt H.C. Wainwright Buy
2020-04-13 Bestätigt H.C. Wainwright Buy
2020-01-09 Eingeleitet National Securities Neutral
2019-05-30 Eingeleitet JP Morgan Neutral
2019-05-29 Eingeleitet Goldman Neutral
2019-01-29 Eingeleitet H.C. Wainwright Buy
2018-11-08 Fortgesetzt Jefferies Buy
2018-04-04 Hochstufung Raymond James Mkt Perform → Outperform
2018-01-02 Eingeleitet Ladenburg Thalmann Buy
2017-11-15 Bestätigt Oppenheimer Outperform
2017-11-15 Herabstufung Raymond James Outperform → Mkt Perform
Alle ansehen

Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten

pulisher
Jun 19, 2025

Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

HC Wainwright Decreases Earnings Estimates for Urogen Pharma - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - FinancialContent

Jun 18, 2025
pulisher
Jun 18, 2025

UroGen Pharma Ltd (NASDAQ: URGN) Stock: A Value Hunter’s Investment? - Stocksregister

Jun 18, 2025
pulisher
Jun 17, 2025

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

UroGen Pharma (NASDAQ:URGN) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 16, 2025

UroGen Investor Drops Cancer Drug Suit Following FDA Approval - Bloomberg Law News

Jun 16, 2025
pulisher
Jun 16, 2025

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about ... - Eagle-Tribune

Jun 16, 2025
pulisher
Jun 16, 2025

Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action - ACCESS Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - PR Newswire

Jun 16, 2025
pulisher
Jun 15, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Scotiabank Raises UroGen Pharma (NASDAQ:URGN) Price Target to $47.00 - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

UroGen Pharma (NASDAQ:URGN) Shares Gap Up After Analyst Upgrade - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Kilgore News Herald

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Victoria Advocate

Jun 13, 2025
pulisher
Jun 13, 2025

Goldman Sachs Increases Price Target for UroGen Pharma (URGN) Af - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Gains Amid Analyst Ratings in Biopharma Sector Russell 1000 - Kalkine Media

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma price target raised to $31 from $10 at Oppenheimer - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote - insights.citeline.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Receives Price Target Boost to $31 After Zusduri Approval | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Soars After FDA Approval and Price Target B - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Why Is UroGen Pharma Stock Trading Higher On Friday?UroGen Pharma (NASDAQ:URGN) - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20 - Asianet Newsable

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen continues to climb after bladder cancer drug approval - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Transcript : UroGen Pharma Ltd.Special Call - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote - Fierce Pharma

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma stock soars as FDA approves Zusduri despite negative panel vote - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves UroGen Pharma’s bladder cancer treatment - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma stock price target raised to $47 from $23 at Scotiabank - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Guggenheim Boosts UroGen Pharma (URGN) Price Target Following FDA Approval | URGN Stock News - GuruFocus

Jun 13, 2025

Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Kapitalisierung:     |  Volumen (24h):